• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Adamas Pharmaceuticals

edit

Adamas Pharmaceuticals, Inc. engages in the development and commercialization of controlled release combination therapeutics to treat healthcare problems, primarily in the areas of infectious diseases and central nervous system disorders. It also develops novel extended release and combination products for symptomatic treatment of dementia. The company was incorporated in 2000 and is headquartered in Emeryville, California with operations in India, the United States, and Singapore.

Recent Milestones

edit

• 
  Adamas Pharmaceuticals received $40M in Series D funding. (10/1/09)
  Posted 10/21/09 at 11:04pm via onbiovc.com
• 
  Adamas Pharmaceuticals added George Rehm as Director. (8/1/08)
  Posted 5/6/13 at 1:15pm
• 
  Adamas Pharmaceuticals received $8M in Series C funding. (7/17/08)
  Posted 2/24/10 at 2:28pm via sec.gov
• 
  Adamas Pharmaceuticals received $13M in Series C funding. (8/6/07)
  Posted 2/24/10 at 2:28pm via sec.gov
• 
  Adamas Pharmaceuticals received $21M in Series B funding. (5/1/05)
  Posted 2/24/10 at 2:28pm via sec.gov
• 
  Adamas Pharmaceuticals added Peter Hadrovic as Chief Commercial Officer .
  Posted 10/21/09 at 11:04pm
• 
  Adamas Pharmaceuticals added Gregory T. Went as Chief Executive Officer & Chairman.
  Posted 10/21/09 at 11:04pm

Videos

Screenshots

edit

Sources

1. SEC D (sec.gov) [edit]
2. SEC D (sec.gov) [edit]
3. SEC D/A (sec.gov) [edit]
4. Adamas Pharmaceuticals, Inc.: Series D $40M (onbiovc.com) [edit]